Globus Medical reported third quarter 2026 worldwide net sales of $763.7 million, representing a 0.7% decrease compared to the same period in 2025, alongside GAAP net income of $141.2 million. The company updated its full-year 2026 revenue guidance to $3.09 billion and announced a $500 million increase to its share repurchase program.
Worldwide net sales were $763.7 million for the third quarter ended September 30, 2026, down 0.7% year-over-year.
GAAP diluted earnings per share increased 18.2% to $1.04 for the quarter.
The Board authorized an additional $500.0 million share repurchase program increase on November 2, 2026.
Full-year 2026 revenue guidance was updated to $3.09 billion.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Globus Medical's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$2.94B
+16.7%
$3.92
+422.7%
18.3%
FY2024
$2.52B
+60.6%
$0.75
-29.9%
4.1%
FY2023
$1.57B
+53.3%
$1.07
-42.2%
7.8%
FY2022
$1.02B
+6.8%
$1.85
+28.5%
18.6%
FY2021
$958.10M
+21.4%
$1.44
+42.6%
15.6%
Frequently asked questions
When is Globus Medical's next earnings date?
Globus Medical has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Globus Medical earn last quarter?
For the quarter ended Sep 2026, Globus Medical reported diluted EPS of $1.04 (+18.2% year over year) on revenue of $763.72M (-0.7%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.